Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Sell

Analyst Rating

Buy

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Neutral

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Gilead Sciences Inc (GILD)

Biological Products, (no Disgnostic Substances)

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

333 LAKESIDE DR
FOSTER CITY, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

01/22/1992

Market Cap

91,718,413,300

Shares Outstanding

1,246,040,000

Weighted SO

1,246,041,895

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

AMGN --.--%

MRK --.--%

ABBV --.--%

JNJ --.--%

BMY --.--%

PFE --.--%

LLY --.--%

AZN --.--%

Beta

0.1990

Last Div

3.0800

Range

62.07-87.87

Chg

-0.6700

Avg Vol

7293535

Mkt Cap

91718413300

Exch

NASDAQ

Country

US

Phone

650 574 3000

DCF Diff

-446.6374

DCF

532.3174

Div Yield

0.0413

P/S

3.2992

EV Multiple

9.2395

P/FV

5.0252

Div Yield %

4.1265

P/E

87.2426

PEG

3.6285

Payout

3.6638

Current Ratio

1.1425

Quick Ratio

0.9545

Cash Ratio

0.2571

DSO

61.2228

DIO

118.8700

Op Cycle

180.0928

DPO

31.5070

CCC

148.5858

Gross Margin

0.7762

Op Margin

0.3640

Pretax Margin

0.0553

Net Margin

0.0379

Eff Tax Rate

0.3283

ROA

0.0197

ROE

0.0521

ROCE

0.2364

NI/EBT

0.6847

EBT/EBIT

0.1520

EBIT/Rev

0.3640

Debt Ratio

0.4358

D/E

1.2773

LT Debt/Cap

0.5409

Total Debt/Cap

0.5609

Int Coverage

10.3785

CF/Debt

0.3199

Equity Multi

2.9309

Rec Turnover

5.9618

Pay Turnover

11.5847

Inv Turnover

3.0706

FA Turnover

5.2001

Asset Turnover

0.5189

OCF/Share

5.9896

FCF/Share

5.5309

Cash/Share

3.3665

OCF/Sales

0.2687

FCF/OCF

0.9234

CF Coverage

0.3199

ST Coverage

4.1265

CapEx Coverage

13.0577

Div&CapEx Cov

1.6860

P/BV

5.0252

P/B

5.0252

P/S

3.2992

P/E

87.2426

P/FCF

13.2983

P/OCF

12.2997

P/CF

12.2997

PEG

3.6285

P/S

3.2992

EV Multiple

9.2395

P/FV

5.0252

DPS

3.0400

Latest Headlines (EST)

GlobeNewswire Inc. Jun 05, 22:38 Xilio Therapeutics Announces Closing of $50.0 Million Public Offering The Motley Fool Feb 09, 19:30 3 Fabulous Dividend Stocks to Buy in February GlobeNewswire Inc. Nov 27, 00:30 Personalized Medicines Market to Surpass Valuation of USD 1352.81 Billion by 2031 | SkyQuest Technology Benzinga Nov 27, 00:30 Personalized Medicines Market to Surpass Valuation of USD 1352.81 Billion by 2031 | SkyQuest Technology GlobeNewswire Inc. Nov 17, 15:30 Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024 The Motley Fool Nov 10, 14:30 3 Spectacular High-Yield Dividend Stocks to Buy in November The Motley Fool Sep 12, 22:11 Why Gilead Sciences Stock Thrashed the Market Today GlobeNewswire Inc. Aug 03, 16:36 Merus gibt die Finanzergebnisse für das zweite Quartal 2024 bekannt und informiert über den aktuellen Geschäftsverlauf The Motley Fool Jan 22, 18:08 Why Gilead Sciences Stock Got Mashed on Monday Benzinga Jan 22, 16:34 S&P 500, Dow Extend All-Time Highs: 'It's A Lot Of Fun For Stock Investors While It Lasts,' Wall Street Veteran Says MarketWatch Jan 22, 16:34 Dow closes above 38,000 for first time and S&P 500 scores back-to-back records MarketWatch Jan 22, 15:36 Dow tops 38,000 for first time as S&P 500 aims at back-to-back records MarketWatch Jan 22, 13:30 Dow, S&P 500 attempt to build on records as earnings season ramps up MarketWatch Jan 22, 12:42 Dow, S&P 500 attempt to build on records as earnings season ramps up MarketWatch Jan 22, 10:36 Dow, S&P 500 attempt to build on records as earnings season ramps up MarketWatch Jan 22, 10:04 Gilead’s stock tumbles toward biggest selloff in more than nine years as lung-cancer trial disappoints MarketWatch Jan 20, 07:43 Can AI and a supercomputer beat the markets? This is one of the hedge funds trying to find out.  MarketWatch Jan 18, 10:32 Medicare drug price negotiations hit critical phase MarketWatch Jan 18, 03:05 Can AI and a supercomputer beat the markets? This is one of the hedge funds trying to find out.  MarketWatch Jan 18, 03:05 Can AI and a supercomputer beat the markets? This is one of the hedge funds trying to find out. 

Revenue Product Segmentation